FDA review of oral MS drug FTY720 extended
Posted: Tue May 25, 2010 12:12 am
Novartis International AG / Novartis announces extension of US regulatory priority review period for FTY720, an investigational once-daily oral multiple sclerosis therapy.
* US Food and Drug Administration (FDA) extends priority review period by three months to September 2010, in line with previously announced expectations............. [Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309 ]